Minocycline attenuates experimental colitis in mice by blocking expression of inducible nitric oxide synthase and matrix metalloproteinases

Tien-Yu Huang; Heng-Cheng Chu; Yi-Ling Lin; Chih-Kung Lin; Tsai-Yuan Hsieh; Wei-Kuo Chang; You-Chen Chao; Ching-Len Liao

doi:10.1016/j.taap.2009.02.026

Minocycline attenuates experimental colitis in mice by blocking expression of inducible nitric oxide synthase and matrix metalloproteinases

Tien-Yu Huang, Heng-Cheng Chu, Yi-Ling Lin, Chih-Kung Lin, Tsai-Yuan Hsieh, Wei-Kuo Chang, You-Chen Chao, Ching-Len Liao

Research output: Contribution to journal › Article › peer-review

51 Citations (Scopus)

Abstract

In addition to its antimicrobial activity, minocycline exerts anti-inflammatory effects in several disease models. However, whether minocycline affects the pathogenesis of inflammatory bowel disease has not been determined. We investigated the effects of minocycline on experimental colitis and its underlying mechanisms. Acute and chronic colitis were induced in mice by treatment with dextran sulfate sodium (DSS) or trinitrobenzene sulfonic acid (TNBS), and the effect of minocycline on colonic injury was assessed clinically and histologically. Prophylactic and therapeutic treatment of mice with minocycline significantly diminished mortality rate and attenuated the severity of DSS-induced acute colitis. Mechanistically, minocycline administration suppressed inducible nitric oxide synthase (iNOS) expression and nitrotyrosine production, inhibited proinflammatory cytokine expression, repressed the elevated mRNA expression of matrix metalloproteinases (MMPs) 2, 3, 9, and 13, diminished the apoptotic index in colonic tissues, and inhibited nitric oxide production in the serum of mice with DSS-induced acute colitis. In DSS-induced chronic colitis, minocycline treatment also reduced body weight loss, improved colonic histology, and blocked expression of iNOS, proinflammatory cytokines, and MMPs from colonic tissues. Similarly, minocycline could ameliorate the severity of TNBS-induced acute colitis in mice by decreasing mortality rate and inhibiting proinflammatory cytokine expression in colonic tissues. These results demonstrate that minocycline protects mice against DSS- and TNBS-induced colitis, probably via inhibition of iNOS and MMP expression in intestinal tissues. Therefore, minocycline is a potential remedy for human inflammatory bowel diseases. © 2009 Elsevier Inc. All rights reserved.

Original language	English
Pages (from-to)	69-82
Number of pages	14
Journal	Toxicology and Applied Pharmacology
Volume	237
Issue number	1
DOIs	https://doi.org/10.1016/j.taap.2009.02.026
Publication status	Published - 2009
Externally published	Yes

Keywords

Colitis
Dextran sulfate sodium
Inducible nitric oxide synthase
Inflammatory bowel diseases
Matrix metalloproteinases
Minocycline
Trinitrobenzene sulfonic acid
antibiotic agent
collagenase 3
dextran sulfate
gelatinase A
gelatinase B
inducible nitric oxide synthase
matrix metalloproteinase
messenger RNA
minocycline
nitric oxide
stromelysin
trinitrobenzenesulfonic acid
acute disease
animal experiment
animal model
antiinflammatory activity
article
chronic disease
colitis
controlled study
disease severity
drug dose comparison
drug dose increase
enteritis
experimental model
immune response
immunohistochemistry
intestine cell
male
mortality
mouse
nonhuman
real time polymerase chain reaction
reverse transcription polymerase chain reaction
Animals
Anti-Bacterial Agents
Anti-Inflammatory Agents
Cytokines
Dextran Sulfate
Disease Models, Animal
Enzyme Inhibitors
Inflammation
Male
Matrix Metalloproteinases
Metronidazole
Mice
Mice, Inbred BALB C
Mice, Inbred C57BL
Nitric Oxide Synthase Type II
RNA, Messenger
Species Specificity
Survival Analysis
Trinitrobenzenesulfonic Acid
Mus

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.taap.2009.02.026

http://www.scopus.com/inward/record.url?eid=2-s2.0-67349085738&partnerID=40&md5=08e9535b89b9729282e1e282978e75d8

Cite this

@article{5425368782344cf693c8604aeb293f10,

title = "Minocycline attenuates experimental colitis in mice by blocking expression of inducible nitric oxide synthase and matrix metalloproteinases",

abstract = "In addition to its antimicrobial activity, minocycline exerts anti-inflammatory effects in several disease models. However, whether minocycline affects the pathogenesis of inflammatory bowel disease has not been determined. We investigated the effects of minocycline on experimental colitis and its underlying mechanisms. Acute and chronic colitis were induced in mice by treatment with dextran sulfate sodium (DSS) or trinitrobenzene sulfonic acid (TNBS), and the effect of minocycline on colonic injury was assessed clinically and histologically. Prophylactic and therapeutic treatment of mice with minocycline significantly diminished mortality rate and attenuated the severity of DSS-induced acute colitis. Mechanistically, minocycline administration suppressed inducible nitric oxide synthase (iNOS) expression and nitrotyrosine production, inhibited proinflammatory cytokine expression, repressed the elevated mRNA expression of matrix metalloproteinases (MMPs) 2, 3, 9, and 13, diminished the apoptotic index in colonic tissues, and inhibited nitric oxide production in the serum of mice with DSS-induced acute colitis. In DSS-induced chronic colitis, minocycline treatment also reduced body weight loss, improved colonic histology, and blocked expression of iNOS, proinflammatory cytokines, and MMPs from colonic tissues. Similarly, minocycline could ameliorate the severity of TNBS-induced acute colitis in mice by decreasing mortality rate and inhibiting proinflammatory cytokine expression in colonic tissues. These results demonstrate that minocycline protects mice against DSS- and TNBS-induced colitis, probably via inhibition of iNOS and MMP expression in intestinal tissues. Therefore, minocycline is a potential remedy for human inflammatory bowel diseases. {\textcopyright} 2009 Elsevier Inc. All rights reserved.",

keywords = "Colitis, Dextran sulfate sodium, Inducible nitric oxide synthase, Inflammatory bowel diseases, Matrix metalloproteinases, Minocycline, Trinitrobenzene sulfonic acid, antibiotic agent, collagenase 3, dextran sulfate, gelatinase A, gelatinase B, inducible nitric oxide synthase, matrix metalloproteinase, messenger RNA, minocycline, nitric oxide, stromelysin, trinitrobenzenesulfonic acid, acute disease, animal experiment, animal model, antiinflammatory activity, article, chronic disease, colitis, controlled study, disease severity, drug dose comparison, drug dose increase, enteritis, experimental model, immune response, immunohistochemistry, intestine cell, male, mortality, mouse, nonhuman, real time polymerase chain reaction, reverse transcription polymerase chain reaction, Animals, Anti-Bacterial Agents, Anti-Inflammatory Agents, Cytokines, Dextran Sulfate, Disease Models, Animal, Enzyme Inhibitors, Inflammation, Male, Matrix Metalloproteinases, Metronidazole, Mice, Mice, Inbred BALB C, Mice, Inbred C57BL, Nitric Oxide Synthase Type II, RNA, Messenger, Species Specificity, Survival Analysis, Trinitrobenzenesulfonic Acid, Mus",

author = "Tien-Yu Huang and Heng-Cheng Chu and Yi-Ling Lin and Chih-Kung Lin and Tsai-Yuan Hsieh and Wei-Kuo Chang and You-Chen Chao and Ching-Len Liao",

note = "被引用次數：29 Export Date: 22 March 2016 CODEN: TXAPA 通訊地址: Chao, Y.-C.; Division of Gastroenterology, Taipei Tzu Chi General Hospital, Taipei, Taiwan 化學物質/CAS: collagenase 3, 175449-82-8; dextran sulfate, 9011-18-1, 9042-14-2; gelatinase A, 146480-35-5; gelatinase B, 146480-36-6; inducible nitric oxide synthase, 501433-35-8; minocycline, 10118-90-8, 11006-27-2, 13614-98-7; nitric oxide, 10102-43-9; stromelysin, 79955-99-0; trinitrobenzenesulfonic acid, 16655-63-3, 2508-19-2; Anti-Bacterial Agents; Anti-Inflammatory Agents; Cytokines; Dextran Sulfate, 9042-14-2; Enzyme Inhibitors; Matrix Metalloproteinases, 3.4.24.-; Metronidazole, 443-48-1; Minocycline, 10118-90-8; Nitric Oxide Synthase Type II, 1.14.13.39; RNA, Messenger; Trinitrobenzenesulfonic Acid, 2508-19-2 製造商： Sigma Aldrich 參考文獻: Amin, A.R., Attur, M.G., Thakker, G.D., Patel, P.D., Vyas, P.R., Patel, R.N., Patel, I.R., Abramson, S.B., A novel mechanism of action of tetracyclines: effects on nitric oxide synthases (1996) Proc. Natl. Acad. Sci. U. S. A., 93, pp. 14014-14019; Amin, A.R., Patel, R.N., Thakker, G.D., Lowenstein, C.J., Attur, M.G., Abramson, S.B., Post-transcriptional regulation of inducible nitric oxide synthase mRNA in murine macrophages by doxycycline and chemically modified tetracyclines (1997) FEBS Lett., 410, pp. 259-264; Archer, S., Measurement of nitric oxide in biological models (1993) Faseb. J., 7, pp. 349-360; Barrie, A., Regueiro, M., Biologic therapy in the management of extraintestinal manifestations of inflammatory bowel disease (2007) Inflamm. Bowel Dis., 13, pp. 1424-1429; Baugh, M.D., Perry, M.J., Hollander, A.P., Davies, D.R., Cross, S.S., Lobo, A.J., Taylor, C.J., Evans, G.S., Matrix metalloproteinase levels are elevated in inflammatory bowel disease (1999) Gastroenterology, 117, pp. 814-822; Beck, P.L., Xavier, R., Wong, J., Ezedi, I., Mashimo, H., Mizoguchi, A., Mizoguchi, E., Podolsky, D.K., Paradoxical roles of different nitric oxide synthase isoforms in colonic injury (2004) Am. J. Physiol. Gastrointest. Liver Physiol., 286, pp. G137-147; Boughton-Smith, N.K., Pathological and therapeutic implications for nitric oxide in inflammatory bowel disease (1994) J. R. Soc. Med., 87, pp. 312-314; Bouma, G., Strober, W., The immunological and genetic basis of inflammatory bowel disease (2003) Nat. Rev. Immunol., 3, pp. 521-533; Bradley, P.P., Priebat, D.A., Christensen, R.D., Rothstein, G., Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker (1982) J. Invest. Dermatol., 78, pp. 206-209; Castaneda, F.E., Walia, B., Vijay-Kumar, M., Patel, N.R., Roser, S., Kolachala, V.L., Rojas, M., Sitaraman, S.V., Targeted deletion of metalloproteinase 9 attenuates experimental colitis in mice: central role of epithelial-derived MMP (2005) Gastroenterology, 129, pp. 1991-2008; Chen, M., Ona, V.O., Li, M., Ferrante, R.J., Fink, K.B., Zhu, S., Bian, J., Friedlander, R.M., Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease (2000) Nat. Med., 6, pp. 797-801; Chu, H.C., Lin, Y.L., Sytwu, H.K., Lin, S.H., Liao, C.L., Chao, Y.C., Effects of minocycline on Fas-mediated fulminant hepatitis in mice (2005) Br. J. Pharmacol., 144, pp. 275-282; Cooper, H.S., Murthy, S.N., Shah, R.S., Sedergran, D.J., Clinicopathologic study of dextran sulfate sodium experimental murine colitis (1993) Lab. Invest., 69, pp. 238-249; Corry, D.B., Rishi, K., Kanellis, J., Kiss, A., Song Lz, L.Z., Xu, J., Feng, L., Kheradmand, F., Decreased allergic lung inflammatory cell egression and increased susceptibility to asphyxiation in MMP2-deficiency (2002) Nat. Immunol., 3, pp. 347-353; Cross, R.K., Wilson, K.T., Nitric oxide in inflammatory bowel disease (2003) Inflamm. Bowel Dis., 9, pp. 179-189; Danese, S., Sans, M., de la Motte, C., Graziani, C., West, G., Phillips, M.H., Pola, R., Fiocchi, C., Angiogenesis as a novel component of inflammatory bowel disease pathogenesis (2006) Gastroenterology, 130, pp. 2060-2073; Dieleman, L.A., Ridwan, B.U., Tennyson, G.S., Beagley, K.W., Bucy, R.P., Elson, C.O., Dextran sulfate sodium-induced colitis occurs in severe combined immunodeficient mice (1994) Gastroenterology, 107, pp. 1643-1652; Du, Y., Ma, Z., Lin, S., Dodel, R.C., Gao, F., Bales, K.R., Triarhou, L.C., Paul, S.M., Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease (2001) Proc. Natl. Acad. Sci. U. S. A., 98, pp. 14669-14674; Dubois, B., Starckx, S., Pagenstecher, A., Oord, J., Arnold, B., Opdenakker, G., Gelatinase B deficiency protects against endotoxin shock (2002) Eur. J. Immunol., 32, pp. 2163-2171; Elson, C.O., Sartor, R.B., Tennyson, G.S., Riddell, R.H., Experimental models of inflammatory bowel disease (1995) Gastroenterology, 109, pp. 1344-1367; Elson, C.O., Beagley, K.W., Sharmanov, A.T., Fujihashi, K., Kiyono, H., Tennyson, G.S., Cong, Y., McGhee, J.R., Hapten-induced model of murine inflammatory bowel disease: mucosa immune responses and protection by tolerance (1996) J. Immunol., 157, pp. 2174-2185; Gionchetti, P., Rizzello, F., Lammers, K.M., Morselli, C., Tambasco, R., Campieri, M., Antimicrobials in the management of inflammatory bowel disease (2006) Digestion, 73 (SUPPL. 1), pp. 77-85; Hautamaki, R.D., Kobayashi, D.K., Senior, R.M., Shapiro, S.D., Requirement for macrophage elastase for cigarette smoke-induced emphysema in mice (1997) Science, 277, pp. 2002-2004; Hokari, R., Kato, S., Matsuzaki, K., Kuroki, M., Iwai, A., Kawaguchi, A., Nagao, S., Miura, S., Reduced sensitivity of inducible nitric oxide synthase-deficient mice to chronic colitis (2001) Free Radic. Biol. Med., 31, pp. 153-163; Hu, J., Van den Steen, P.E., Sang, Q.X., Opdenakker, G., Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases (2007) Nat. Rev. Drug Discov., 6, pp. 480-498; Kankuri, E., Vaali, K., Knowles, R.G., Lahde, M., Korpela, R., Vapaatalo, H., Moilanen, E., Suppression of acute experimental colitis by a highly selective inducible nitric-oxide synthase inhibitor, N-[3-(aminomethyl)benzyl]acetamidine (2001) J. Pharmacol. Exp. Ther., 298, pp. 1128-1132; Keane, J., Gershon, S., Wise, R.P., Mirabile-Levens, E., Kasznica, J., Schwieterman, W.D., Siegel, J.N., Braun, M.M., Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent (2001) N. Engl. J. Med., 345, pp. 1098-1104; Kielian, T., Esen, N., Liu, S., Phulwani, N.K., Syed, M.M., Phillips, N., Nishina, K., Ruhe, J.J., Minocycline modulates neuroinflammation independently of its antimicrobial activity in Staphylococcus aureus-induced brain abscess (2007) Am. J. Pathol., 171, pp. 1199-1214; Kirkegaard, T., Hansen, A., Bruun, E., Brynskov, J., Expression and localisation of matrix metalloproteinases and their natural inhibitors in fistulae of patients with Crohn's disease (2004) Gut, 53, pp. 701-709; Kloppenburg, M., Verweij, C.L., Miltenburg, A.M., Verhoeven, A.J., Daha, M.R., Dijkmans, B.A., Breedveld, F.C., The influence of tetracyclines on T cell activation (1995) Clin. Exp. Immunol., 102, pp. 635-641; Koistinaho, M., Malm, T.M., Kettunen, M.I., Goldsteins, G., Starckx, S., Kauppinen, R.A., Opdenakker, G., Koistinaho, J., Minocycline protects against permanent cerebral ischemia in wild type but not in matrix metalloprotease-9-deficient mice (2005) J. Cereb. Blood Flow Metab., 25, pp. 460-467; Korzenik, J.R., Podolsky, D.K., Evolving knowledge and therapy of inflammatory bowel disease (2006) Nat. Rev. Drug Discov., 5, pp. 197-209; Krieglstein, C.F., Cerwinka, W.H., Laroux, F.S., Salter, J.W., Russell, J.M., Schuermann, G., Grisham, M.B., Granger, D.N., Regulation of murine intestinal inflammation by reactive metabolites of oxygen and nitrogen: divergent roles of superoxide and nitric oxide (2001) J. Exp. Med., 194, pp. 1207-1218; Lee, C.Z., Yao, J.S., Huang, Y., Zhai, W., Liu, W., Guglielmo, B.J., Lin, E., Young, W.L., Dose-response effect of tetracyclines on cerebral matrix metalloproteinase-9 after vascular endothelial growth factor hyperstimulation (2006) J. Cereb. Blood Flow Metab., 26, pp. 1157-1164; Macdonald, T.T., Monteleone, G., Immunity, inflammation, and allergy in the gut (2005) Science, 307, pp. 1920-1925; Machado, L.S., Kozak, A., Ergul, A., Hess, D.C., Borlongan, C.V., Fagan, S.C., Delayed minocycline inhibits ischemia-activated matrix metalloproteinases 2 and 9 after experimental stroke (2006) BMC Neurosci., 7, p. 56; Mahler, M., Bristol, I.J., Leiter, E.H., Workman, A.E., Birkenmeier, E.H., Elson, C.O., Sundberg, J.P., Differential susceptibility of inbred mouse strains to dextran sulfate sodium-induced colitis (1998) Am. J. Physiol., 274, pp. G544-551; Martinez, J.A., Williams, C.S., Amann, J.M., Ellis, T.C., Moreno-Miralles, I., Washington, M.K., Gregoli, P., Hiebert, S.W., Deletion of Mtgr1 sensitizes the colonic epithelium to dextran sodium sulfate-induced colitis (2006) Gastroenterology, 131, pp. 579-588; Medina, C., Radomski, M.W., Role of matrix metalloproteinases in intestinal inflammation (2006) J. Pharmacol. Exp. Ther., 318, pp. 933-938; Medina, C., Videla, S., Radomski, A., Radomski, M.W., Antolin, M., Guarner, F., Vilaseca, J., Malagelada, J.R., Increased activity and expression of matrix metalloproteinase-9 in a rat model of distal colitis (2003) Am. J. Physiol. Gastrointest. Liver Physiol., 284, pp. G116-122; Medina, C., Santana, A., Paz, M.C., Diaz-Gonzalez, F., Farre, E., Salas, A., Radomski, M.W., Quintero, E., Matrix metalloproteinase-9 modulates intestinal injury in rats with transmural colitis (2006) J. Leukoc. Biol., 79, pp. 954-962; Meijer, M.J., Mieremet-Ooms, M.A., van der Zon, A.M., van Duijn, W., van Hogezand, R.A., Sier, C.F., Hommes, D.W., Verspaget, H.W., Increased mucosal matrix metalloproteinase-1, -2, -3 and -9 activity in patients with inflammatory bowel disease and the relation with Crohn's disease phenotype (2007) Dig. Liver Dis., 39, pp. 733-739; Menchen, L.A., Colon, A.L., Moro, M.A., Leza, J.C., Lizasoain, I., Menchen, P., Alvarez, E., Lorenzo, P., N-(3-(aminomethyl)benzyl)acetamidine, an inducible nitric oxide synthase inhibitor, decreases colonic inflammation induced by trinitrobenzene sulphonic acid in rats (2001) Life Sci., 69, pp. 479-491; Morris, G.P., Beck, P.L., Herridge, M.S., Depew, W.T., Szewczuk, M.R., Wallace, J.L., Hapten-induced model of chronic inflammation and ulceration in the rat colon (1989) Gastroenterology, 96, pp. 795-803; Muller-Pillasch, F., Gress, T.M., Yamaguchi, H., Geng, M., Adler, G., Menke, A., The influence of transforming growth factor beta 1 on the expression of genes coding for matrix metalloproteinases and tissue inhibitors of metalloproteinases during regeneration from cerulein-induced pancreatitis (1997) Pancreas, 15, pp. 168-175; Munkholm, P., Langholz, E., Davidsen, M., Binder, V., Frequency of glucocorticoid resistance and dependency in Crohn's disease (1994) Gut, 35, pp. 360-362; Naito, Y., Yoshikawa, T., Role of matrix metalloproteinases in inflammatory bowel disease (2005) Mol. Aspects Med., 26, pp. 379-390; Naito, Y., Takagi, T., Kuroda, M., Katada, K., Ichikawa, H., Kokura, S., Yoshida, N., Yoshikawa, T., An orally active matrix metalloproteinase inhibitor, ONO-4817, reduces dextran sulfate sodium-induced colitis in mice (2004) Inflamm. Res., 53, pp. 462-468; Obermeier, F., Kojouharoff, G., Hans, W., Scholmerich, J., Gross, V., Falk, W., Interferon-gamma (IFN-gamma)- and tumour necrosis factor (TNF)-induced nitric oxide as toxic effector molecule in chronic dextran sulphate sodium (DSS)-induced colitis in mice (1999) Clin. Exp. Immunol., 116, pp. 238-245; Ohkawara, T., Nishihira, J., Takeda, H., Hige, S., Kato, M., Sugiyama, T., Iwanaga, T., Asaka, M., Amelioration of dextran sulfate sodium-induced colitis by anti-macrophage migration inhibitory factor antibody in mice (2002) Gastroenterology, 123, pp. 256-270; Okayasu, I., Hatakeyama, S., Yamada, M., Ohkusa, T., Inagaki, Y., Nakaya, R., A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice (1990) Gastroenterology, 98, pp. 694-702; Onderdonk, A.B., Hermos, J.A., Dzink, J.L., Bartlett, J.G., Protective effect of metronidazole in experimental ulcerative colitis (1978) Gastroenterology, 74, pp. 521-526; Opdenakker, G., Nelissen, I., Van Damme, J., Functional roles and therapeutic targeting of gelatinase B and chemokines in multiple sclerosis (2003) Lancet Neurol., 2, pp. 747-756; Rath, H.C., Schultz, M., Freitag, R., Dieleman, L.A., Li, F., Linde, H.J., Scholmerich, J., Sartor, R.B., Different subsets of enteric bacteria induce and perpetuate experimental colitis in rats and mice (2001) Infect. Immun., 69, pp. 2277-2285; Rifkin, B.R., Vernillo, A.T., Golub, L.M., Blocking periodontal disease progression by inhibiting tissue-destructive enzymes: a potential therapeutic role for tetracyclines and their chemically-modified analogs (1993) J. Periodontol., 64, pp. 819-827; Sadlack, B., Merz, H., Schorle, H., Schimpl, A., Feller, A.C., Horak, I., Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene (1993) Cell, 75, pp. 253-261; Sapadin, A.N., Fleischmajer, R., Tetracyclines: nonantibiotic properties and their clinical implications (2006) J. Am. Acad. Dermatol., 54, pp. 258-265; Sartor, R.B., Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics (2004) Gastroenterology, 126, pp. 1620-1633; Sellon, R.K., Tonkonogy, S., Schultz, M., Dieleman, L.A., Grenther, W., Balish, E., Rennick, D.M., Sartor, R.B., Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice (1998) Infect. Immun., 66, pp. 5224-5231; Shenefelt, P.D., Pyoderma gangrenosum associated with cystic acne and hidradenitis suppurativa controlled by adding minocycline and sulfasalazine to the treatment regimen (1996) Cutis, 57, pp. 315-319; Sorsa, T., Tjaderhane, L., Konttinen, Y.T., Lauhio, A., Salo, T., Lee, H.M., Golub, L.M., Mantyla, P., Matrix metalloproteinases: contribution to pathogenesis, diagnosis and treatment of periodontal inflammation (2006) Ann. Med., 38, pp. 306-321; Sriram, K., Miller, D.B., O'Callaghan, J.P., Minocycline attenuates microglial activation but fails to mitigate striatal dopaminergic neurotoxicity: role of tumor necrosis factor-alpha (2006) J. Neurochem., 96, pp. 706-718; Stone, M., Fortin, P.R., Pacheco-Tena, C., Inman, R.D., Should tetracycline treatment be used more extensively for rheumatoid arthritis? Metaanalysis demonstrates clinical benefit with reduction in disease activity (2003) J. Rheumatol., 30, pp. 2112-2122; Sutton, T.A., Kelly, K.J., Mang, H.E., Plotkin, Z., Sandoval, R.M., Dagher, P.C., Minocycline reduces renal microvascular leakage in a rat model of ischemic renal injury (2005) Am. J. Physiol. Renal. Physiol., 288, pp. F91-97; Tamaki, H., Nakamura, H., Nishio, A., Nakase, H., Ueno, S., Uza, N., Kido, M., Chiba, T., Human thioredoxin-1 ameliorates experimental murine colitis in association with suppressed macrophage inhibitory factor production (2006) Gastroenterology, 131, pp. 1110-1121; Tamargo, R.J., Bok, R.A., Brem, H., Angiogenesis inhibition by minocycline (1991) Cancer Res., 51, pp. 672-675; Tessner, T.G., Cohn, S.M., Schloemann, S., Stenson, W.F., Prostaglandins prevent decreased epithelial cell proliferation associated with dextran sodium sulfate injury in mice (1998) Gastroenterology, 115, pp. 874-882; Thomas, M., Ashizawa, T., Jankovic, J., Minocycline in Huntington's disease: a pilot study (2004) Mov. Disord., 19, pp. 692-695; Truelove, S.C., Witts, L.J., Cortisone in ulcerative colitis; final report on a therapeutic trial (1955) Br. Med. J., 2, pp. 1041-1048; Van den Steen, P.E., Proost, P., Grillet, B., Brand, D.D., Kang, A.H., Van Damme, J., Opdenakker, G., Cleavage of denatured natural collagen type II by neutrophil gelatinase B reveals enzyme specificity, post-translational modifications in the substrate, and the formation of remnant epitopes in rheumatoid arthritis (2002) Faseb J., 16, pp. 379-389; Van Lint, P., Wielockx, B., Puimege, L., Noel, A., Lopez-Otin, C., Libert, C., Resistance of collagenase-2 (matrix metalloproteinase-8)-deficient mice to TNF-induced lethal hepatitis (2005) J. Immunol., 175, pp. 7642-7649; Vizoso, F.J., Gonzalez, L.O., Corte, M.D., Corte, M.G., Bongera, M., Martinez, A., Martin, A., Gava, R.R., Collagenase-3 (MMP-13) expression by inflamed mucosa in inflammatory bowel disease (2006) Scand. J. Gastroenterol., 41, pp. 1050-1055; Warris, A., Bjorneklett, A., Gaustad, P., Invasive pulmonary aspergillosis associated with infliximab therapy (2001) N. Engl. J. Med., 344, pp. 1099-1100; Williams, K.L., Fuller, C.R., Dieleman, L.A., DaCosta, C.M., Haldeman, K.M., Sartor, R.B., Lund, P.K., Enhanced survival and mucosal repair after dextran sodium sulfate-induced colitis in transgenic mice that overexpress growth hormone (2001) Gastroenterology, 120, pp. 925-937; Wirtz, S., Neurath, M.F., Animal models of intestinal inflammation: new insights into the molecular pathogenesis and immunotherapy of inflammatory bowel disease (2000) Int. J. Colorectal Dis., 15, pp. 144-160; Yue, G., Lai, P.S., Yin, K., Sun, F.F., Nagele, R.G., Liu, X., Linask, K.K., Wong, P.Y., Colon epithelial cell death in 2,4,6-trinitrobenzenesulfonic acid-induced colitis is associated with increased inducible nitric-oxide synthase expression and peroxynitrite production (2001) J. Pharmacol. Exp. Ther., 297, pp. 915-925; Zhu, S., Stavrovskaya, I.G., Drozda, M., Kim, B.Y., Ona, V., Li, M., Sarang, S., Friedlander, R.M., Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice (2002) Nature, 417, pp. 74-78; Zingarelli, B., Szabo, C., Salzman, A.L., Reduced oxidative and nitrosative damage in murine experimental colitis in the absence of inducible nitric oxide synthase (1999) Gut, 45, pp. 199-209",

year = "2009",

doi = "10.1016/j.taap.2009.02.026",

language = "English",

volume = "237",

pages = "69--82",

journal = "Toxicology and Applied Pharmacology",

issn = "0041-008X",

publisher = "Academic Press Inc.",

number = "1",

}

TY - JOUR

T1 - Minocycline attenuates experimental colitis in mice by blocking expression of inducible nitric oxide synthase and matrix metalloproteinases

AU - Huang, Tien-Yu

AU - Chu, Heng-Cheng

AU - Lin, Yi-Ling

AU - Lin, Chih-Kung

AU - Hsieh, Tsai-Yuan

AU - Chang, Wei-Kuo

AU - Chao, You-Chen

AU - Liao, Ching-Len

N1 - 被引用次數：29 Export Date: 22 March 2016 CODEN: TXAPA 通訊地址: Chao, Y.-C.; Division of Gastroenterology, Taipei Tzu Chi General Hospital, Taipei, Taiwan 化學物質/CAS: collagenase 3, 175449-82-8; dextran sulfate, 9011-18-1, 9042-14-2; gelatinase A, 146480-35-5; gelatinase B, 146480-36-6; inducible nitric oxide synthase, 501433-35-8; minocycline, 10118-90-8, 11006-27-2, 13614-98-7; nitric oxide, 10102-43-9; stromelysin, 79955-99-0; trinitrobenzenesulfonic acid, 16655-63-3, 2508-19-2; Anti-Bacterial Agents; Anti-Inflammatory Agents; Cytokines; Dextran Sulfate, 9042-14-2; Enzyme Inhibitors; Matrix Metalloproteinases, 3.4.24.-; Metronidazole, 443-48-1; Minocycline, 10118-90-8; Nitric Oxide Synthase Type II, 1.14.13.39; RNA, Messenger; Trinitrobenzenesulfonic Acid, 2508-19-2 製造商： Sigma Aldrich 參考文獻: Amin, A.R., Attur, M.G., Thakker, G.D., Patel, P.D., Vyas, P.R., Patel, R.N., Patel, I.R., Abramson, S.B., A novel mechanism of action of tetracyclines: effects on nitric oxide synthases (1996) Proc. Natl. Acad. Sci. U. S. A., 93, pp. 14014-14019; Amin, A.R., Patel, R.N., Thakker, G.D., Lowenstein, C.J., Attur, M.G., Abramson, S.B., Post-transcriptional regulation of inducible nitric oxide synthase mRNA in murine macrophages by doxycycline and chemically modified tetracyclines (1997) FEBS Lett., 410, pp. 259-264; Archer, S., Measurement of nitric oxide in biological models (1993) Faseb. J., 7, pp. 349-360; Barrie, A., Regueiro, M., Biologic therapy in the management of extraintestinal manifestations of inflammatory bowel disease (2007) Inflamm. Bowel Dis., 13, pp. 1424-1429; Baugh, M.D., Perry, M.J., Hollander, A.P., Davies, D.R., Cross, S.S., Lobo, A.J., Taylor, C.J., Evans, G.S., Matrix metalloproteinase levels are elevated in inflammatory bowel disease (1999) Gastroenterology, 117, pp. 814-822; Beck, P.L., Xavier, R., Wong, J., Ezedi, I., Mashimo, H., Mizoguchi, A., Mizoguchi, E., Podolsky, D.K., Paradoxical roles of different nitric oxide synthase isoforms in colonic injury (2004) Am. J. Physiol. Gastrointest. Liver Physiol., 286, pp. G137-147; Boughton-Smith, N.K., Pathological and therapeutic implications for nitric oxide in inflammatory bowel disease (1994) J. R. Soc. Med., 87, pp. 312-314; Bouma, G., Strober, W., The immunological and genetic basis of inflammatory bowel disease (2003) Nat. Rev. Immunol., 3, pp. 521-533; Bradley, P.P., Priebat, D.A., Christensen, R.D., Rothstein, G., Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker (1982) J. Invest. Dermatol., 78, pp. 206-209; Castaneda, F.E., Walia, B., Vijay-Kumar, M., Patel, N.R., Roser, S., Kolachala, V.L., Rojas, M., Sitaraman, S.V., Targeted deletion of metalloproteinase 9 attenuates experimental colitis in mice: central role of epithelial-derived MMP (2005) Gastroenterology, 129, pp. 1991-2008; Chen, M., Ona, V.O., Li, M., Ferrante, R.J., Fink, K.B., Zhu, S., Bian, J., Friedlander, R.M., Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease (2000) Nat. Med., 6, pp. 797-801; Chu, H.C., Lin, Y.L., Sytwu, H.K., Lin, S.H., Liao, C.L., Chao, Y.C., Effects of minocycline on Fas-mediated fulminant hepatitis in mice (2005) Br. J. Pharmacol., 144, pp. 275-282; Cooper, H.S., Murthy, S.N., Shah, R.S., Sedergran, D.J., Clinicopathologic study of dextran sulfate sodium experimental murine colitis (1993) Lab. Invest., 69, pp. 238-249; Corry, D.B., Rishi, K., Kanellis, J., Kiss, A., Song Lz, L.Z., Xu, J., Feng, L., Kheradmand, F., Decreased allergic lung inflammatory cell egression and increased susceptibility to asphyxiation in MMP2-deficiency (2002) Nat. Immunol., 3, pp. 347-353; Cross, R.K., Wilson, K.T., Nitric oxide in inflammatory bowel disease (2003) Inflamm. Bowel Dis., 9, pp. 179-189; Danese, S., Sans, M., de la Motte, C., Graziani, C., West, G., Phillips, M.H., Pola, R., Fiocchi, C., Angiogenesis as a novel component of inflammatory bowel disease pathogenesis (2006) Gastroenterology, 130, pp. 2060-2073; Dieleman, L.A., Ridwan, B.U., Tennyson, G.S., Beagley, K.W., Bucy, R.P., Elson, C.O., Dextran sulfate sodium-induced colitis occurs in severe combined immunodeficient mice (1994) Gastroenterology, 107, pp. 1643-1652; Du, Y., Ma, Z., Lin, S., Dodel, R.C., Gao, F., Bales, K.R., Triarhou, L.C., Paul, S.M., Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease (2001) Proc. Natl. Acad. Sci. U. S. A., 98, pp. 14669-14674; Dubois, B., Starckx, S., Pagenstecher, A., Oord, J., Arnold, B., Opdenakker, G., Gelatinase B deficiency protects against endotoxin shock (2002) Eur. J. Immunol., 32, pp. 2163-2171; Elson, C.O., Sartor, R.B., Tennyson, G.S., Riddell, R.H., Experimental models of inflammatory bowel disease (1995) Gastroenterology, 109, pp. 1344-1367; Elson, C.O., Beagley, K.W., Sharmanov, A.T., Fujihashi, K., Kiyono, H., Tennyson, G.S., Cong, Y., McGhee, J.R., Hapten-induced model of murine inflammatory bowel disease: mucosa immune responses and protection by tolerance (1996) J. Immunol., 157, pp. 2174-2185; Gionchetti, P., Rizzello, F., Lammers, K.M., Morselli, C., Tambasco, R., Campieri, M., Antimicrobials in the management of inflammatory bowel disease (2006) Digestion, 73 (SUPPL. 1), pp. 77-85; Hautamaki, R.D., Kobayashi, D.K., Senior, R.M., Shapiro, S.D., Requirement for macrophage elastase for cigarette smoke-induced emphysema in mice (1997) Science, 277, pp. 2002-2004; Hokari, R., Kato, S., Matsuzaki, K., Kuroki, M., Iwai, A., Kawaguchi, A., Nagao, S., Miura, S., Reduced sensitivity of inducible nitric oxide synthase-deficient mice to chronic colitis (2001) Free Radic. Biol. Med., 31, pp. 153-163; Hu, J., Van den Steen, P.E., Sang, Q.X., Opdenakker, G., Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases (2007) Nat. Rev. Drug Discov., 6, pp. 480-498; Kankuri, E., Vaali, K., Knowles, R.G., Lahde, M., Korpela, R., Vapaatalo, H., Moilanen, E., Suppression of acute experimental colitis by a highly selective inducible nitric-oxide synthase inhibitor, N-[3-(aminomethyl)benzyl]acetamidine (2001) J. Pharmacol. Exp. Ther., 298, pp. 1128-1132; Keane, J., Gershon, S., Wise, R.P., Mirabile-Levens, E., Kasznica, J., Schwieterman, W.D., Siegel, J.N., Braun, M.M., Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent (2001) N. Engl. J. Med., 345, pp. 1098-1104; Kielian, T., Esen, N., Liu, S., Phulwani, N.K., Syed, M.M., Phillips, N., Nishina, K., Ruhe, J.J., Minocycline modulates neuroinflammation independently of its antimicrobial activity in Staphylococcus aureus-induced brain abscess (2007) Am. J. Pathol., 171, pp. 1199-1214; Kirkegaard, T., Hansen, A., Bruun, E., Brynskov, J., Expression and localisation of matrix metalloproteinases and their natural inhibitors in fistulae of patients with Crohn's disease (2004) Gut, 53, pp. 701-709; Kloppenburg, M., Verweij, C.L., Miltenburg, A.M., Verhoeven, A.J., Daha, M.R., Dijkmans, B.A., Breedveld, F.C., The influence of tetracyclines on T cell activation (1995) Clin. Exp. Immunol., 102, pp. 635-641; Koistinaho, M., Malm, T.M., Kettunen, M.I., Goldsteins, G., Starckx, S., Kauppinen, R.A., Opdenakker, G., Koistinaho, J., Minocycline protects against permanent cerebral ischemia in wild type but not in matrix metalloprotease-9-deficient mice (2005) J. Cereb. Blood Flow Metab., 25, pp. 460-467; Korzenik, J.R., Podolsky, D.K., Evolving knowledge and therapy of inflammatory bowel disease (2006) Nat. Rev. Drug Discov., 5, pp. 197-209; Krieglstein, C.F., Cerwinka, W.H., Laroux, F.S., Salter, J.W., Russell, J.M., Schuermann, G., Grisham, M.B., Granger, D.N., Regulation of murine intestinal inflammation by reactive metabolites of oxygen and nitrogen: divergent roles of superoxide and nitric oxide (2001) J. Exp. Med., 194, pp. 1207-1218; Lee, C.Z., Yao, J.S., Huang, Y., Zhai, W., Liu, W., Guglielmo, B.J., Lin, E., Young, W.L., Dose-response effect of tetracyclines on cerebral matrix metalloproteinase-9 after vascular endothelial growth factor hyperstimulation (2006) J. Cereb. Blood Flow Metab., 26, pp. 1157-1164; Macdonald, T.T., Monteleone, G., Immunity, inflammation, and allergy in the gut (2005) Science, 307, pp. 1920-1925; Machado, L.S., Kozak, A., Ergul, A., Hess, D.C., Borlongan, C.V., Fagan, S.C., Delayed minocycline inhibits ischemia-activated matrix metalloproteinases 2 and 9 after experimental stroke (2006) BMC Neurosci., 7, p. 56; Mahler, M., Bristol, I.J., Leiter, E.H., Workman, A.E., Birkenmeier, E.H., Elson, C.O., Sundberg, J.P., Differential susceptibility of inbred mouse strains to dextran sulfate sodium-induced colitis (1998) Am. J. Physiol., 274, pp. G544-551; Martinez, J.A., Williams, C.S., Amann, J.M., Ellis, T.C., Moreno-Miralles, I., Washington, M.K., Gregoli, P., Hiebert, S.W., Deletion of Mtgr1 sensitizes the colonic epithelium to dextran sodium sulfate-induced colitis (2006) Gastroenterology, 131, pp. 579-588; Medina, C., Radomski, M.W., Role of matrix metalloproteinases in intestinal inflammation (2006) J. Pharmacol. Exp. Ther., 318, pp. 933-938; Medina, C., Videla, S., Radomski, A., Radomski, M.W., Antolin, M., Guarner, F., Vilaseca, J., Malagelada, J.R., Increased activity and expression of matrix metalloproteinase-9 in a rat model of distal colitis (2003) Am. J. Physiol. Gastrointest. Liver Physiol., 284, pp. G116-122; Medina, C., Santana, A., Paz, M.C., Diaz-Gonzalez, F., Farre, E., Salas, A., Radomski, M.W., Quintero, E., Matrix metalloproteinase-9 modulates intestinal injury in rats with transmural colitis (2006) J. Leukoc. Biol., 79, pp. 954-962; Meijer, M.J., Mieremet-Ooms, M.A., van der Zon, A.M., van Duijn, W., van Hogezand, R.A., Sier, C.F., Hommes, D.W., Verspaget, H.W., Increased mucosal matrix metalloproteinase-1, -2, -3 and -9 activity in patients with inflammatory bowel disease and the relation with Crohn's disease phenotype (2007) Dig. Liver Dis., 39, pp. 733-739; Menchen, L.A., Colon, A.L., Moro, M.A., Leza, J.C., Lizasoain, I., Menchen, P., Alvarez, E., Lorenzo, P., N-(3-(aminomethyl)benzyl)acetamidine, an inducible nitric oxide synthase inhibitor, decreases colonic inflammation induced by trinitrobenzene sulphonic acid in rats (2001) Life Sci., 69, pp. 479-491; Morris, G.P., Beck, P.L., Herridge, M.S., Depew, W.T., Szewczuk, M.R., Wallace, J.L., Hapten-induced model of chronic inflammation and ulceration in the rat colon (1989) Gastroenterology, 96, pp. 795-803; Muller-Pillasch, F., Gress, T.M., Yamaguchi, H., Geng, M., Adler, G., Menke, A., The influence of transforming growth factor beta 1 on the expression of genes coding for matrix metalloproteinases and tissue inhibitors of metalloproteinases during regeneration from cerulein-induced pancreatitis (1997) Pancreas, 15, pp. 168-175; Munkholm, P., Langholz, E., Davidsen, M., Binder, V., Frequency of glucocorticoid resistance and dependency in Crohn's disease (1994) Gut, 35, pp. 360-362; Naito, Y., Yoshikawa, T., Role of matrix metalloproteinases in inflammatory bowel disease (2005) Mol. Aspects Med., 26, pp. 379-390; Naito, Y., Takagi, T., Kuroda, M., Katada, K., Ichikawa, H., Kokura, S., Yoshida, N., Yoshikawa, T., An orally active matrix metalloproteinase inhibitor, ONO-4817, reduces dextran sulfate sodium-induced colitis in mice (2004) Inflamm. Res., 53, pp. 462-468; Obermeier, F., Kojouharoff, G., Hans, W., Scholmerich, J., Gross, V., Falk, W., Interferon-gamma (IFN-gamma)- and tumour necrosis factor (TNF)-induced nitric oxide as toxic effector molecule in chronic dextran sulphate sodium (DSS)-induced colitis in mice (1999) Clin. Exp. Immunol., 116, pp. 238-245; Ohkawara, T., Nishihira, J., Takeda, H., Hige, S., Kato, M., Sugiyama, T., Iwanaga, T., Asaka, M., Amelioration of dextran sulfate sodium-induced colitis by anti-macrophage migration inhibitory factor antibody in mice (2002) Gastroenterology, 123, pp. 256-270; Okayasu, I., Hatakeyama, S., Yamada, M., Ohkusa, T., Inagaki, Y., Nakaya, R., A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice (1990) Gastroenterology, 98, pp. 694-702; Onderdonk, A.B., Hermos, J.A., Dzink, J.L., Bartlett, J.G., Protective effect of metronidazole in experimental ulcerative colitis (1978) Gastroenterology, 74, pp. 521-526; Opdenakker, G., Nelissen, I., Van Damme, J., Functional roles and therapeutic targeting of gelatinase B and chemokines in multiple sclerosis (2003) Lancet Neurol., 2, pp. 747-756; Rath, H.C., Schultz, M., Freitag, R., Dieleman, L.A., Li, F., Linde, H.J., Scholmerich, J., Sartor, R.B., Different subsets of enteric bacteria induce and perpetuate experimental colitis in rats and mice (2001) Infect. Immun., 69, pp. 2277-2285; Rifkin, B.R., Vernillo, A.T., Golub, L.M., Blocking periodontal disease progression by inhibiting tissue-destructive enzymes: a potential therapeutic role for tetracyclines and their chemically-modified analogs (1993) J. Periodontol., 64, pp. 819-827; Sadlack, B., Merz, H., Schorle, H., Schimpl, A., Feller, A.C., Horak, I., Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene (1993) Cell, 75, pp. 253-261; Sapadin, A.N., Fleischmajer, R., Tetracyclines: nonantibiotic properties and their clinical implications (2006) J. Am. Acad. Dermatol., 54, pp. 258-265; Sartor, R.B., Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics (2004) Gastroenterology, 126, pp. 1620-1633; Sellon, R.K., Tonkonogy, S., Schultz, M., Dieleman, L.A., Grenther, W., Balish, E., Rennick, D.M., Sartor, R.B., Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice (1998) Infect. Immun., 66, pp. 5224-5231; Shenefelt, P.D., Pyoderma gangrenosum associated with cystic acne and hidradenitis suppurativa controlled by adding minocycline and sulfasalazine to the treatment regimen (1996) Cutis, 57, pp. 315-319; Sorsa, T., Tjaderhane, L., Konttinen, Y.T., Lauhio, A., Salo, T., Lee, H.M., Golub, L.M., Mantyla, P., Matrix metalloproteinases: contribution to pathogenesis, diagnosis and treatment of periodontal inflammation (2006) Ann. Med., 38, pp. 306-321; Sriram, K., Miller, D.B., O'Callaghan, J.P., Minocycline attenuates microglial activation but fails to mitigate striatal dopaminergic neurotoxicity: role of tumor necrosis factor-alpha (2006) J. Neurochem., 96, pp. 706-718; Stone, M., Fortin, P.R., Pacheco-Tena, C., Inman, R.D., Should tetracycline treatment be used more extensively for rheumatoid arthritis? Metaanalysis demonstrates clinical benefit with reduction in disease activity (2003) J. Rheumatol., 30, pp. 2112-2122; Sutton, T.A., Kelly, K.J., Mang, H.E., Plotkin, Z., Sandoval, R.M., Dagher, P.C., Minocycline reduces renal microvascular leakage in a rat model of ischemic renal injury (2005) Am. J. Physiol. Renal. Physiol., 288, pp. F91-97; Tamaki, H., Nakamura, H., Nishio, A., Nakase, H., Ueno, S., Uza, N., Kido, M., Chiba, T., Human thioredoxin-1 ameliorates experimental murine colitis in association with suppressed macrophage inhibitory factor production (2006) Gastroenterology, 131, pp. 1110-1121; Tamargo, R.J., Bok, R.A., Brem, H., Angiogenesis inhibition by minocycline (1991) Cancer Res., 51, pp. 672-675; Tessner, T.G., Cohn, S.M., Schloemann, S., Stenson, W.F., Prostaglandins prevent decreased epithelial cell proliferation associated with dextran sodium sulfate injury in mice (1998) Gastroenterology, 115, pp. 874-882; Thomas, M., Ashizawa, T., Jankovic, J., Minocycline in Huntington's disease: a pilot study (2004) Mov. Disord., 19, pp. 692-695; Truelove, S.C., Witts, L.J., Cortisone in ulcerative colitis; final report on a therapeutic trial (1955) Br. Med. J., 2, pp. 1041-1048; Van den Steen, P.E., Proost, P., Grillet, B., Brand, D.D., Kang, A.H., Van Damme, J., Opdenakker, G., Cleavage of denatured natural collagen type II by neutrophil gelatinase B reveals enzyme specificity, post-translational modifications in the substrate, and the formation of remnant epitopes in rheumatoid arthritis (2002) Faseb J., 16, pp. 379-389; Van Lint, P., Wielockx, B., Puimege, L., Noel, A., Lopez-Otin, C., Libert, C., Resistance of collagenase-2 (matrix metalloproteinase-8)-deficient mice to TNF-induced lethal hepatitis (2005) J. Immunol., 175, pp. 7642-7649; Vizoso, F.J., Gonzalez, L.O., Corte, M.D., Corte, M.G., Bongera, M., Martinez, A., Martin, A., Gava, R.R., Collagenase-3 (MMP-13) expression by inflamed mucosa in inflammatory bowel disease (2006) Scand. J. Gastroenterol., 41, pp. 1050-1055; Warris, A., Bjorneklett, A., Gaustad, P., Invasive pulmonary aspergillosis associated with infliximab therapy (2001) N. Engl. J. Med., 344, pp. 1099-1100; Williams, K.L., Fuller, C.R., Dieleman, L.A., DaCosta, C.M., Haldeman, K.M., Sartor, R.B., Lund, P.K., Enhanced survival and mucosal repair after dextran sodium sulfate-induced colitis in transgenic mice that overexpress growth hormone (2001) Gastroenterology, 120, pp. 925-937; Wirtz, S., Neurath, M.F., Animal models of intestinal inflammation: new insights into the molecular pathogenesis and immunotherapy of inflammatory bowel disease (2000) Int. J. Colorectal Dis., 15, pp. 144-160; Yue, G., Lai, P.S., Yin, K., Sun, F.F., Nagele, R.G., Liu, X., Linask, K.K., Wong, P.Y., Colon epithelial cell death in 2,4,6-trinitrobenzenesulfonic acid-induced colitis is associated with increased inducible nitric-oxide synthase expression and peroxynitrite production (2001) J. Pharmacol. Exp. Ther., 297, pp. 915-925; Zhu, S., Stavrovskaya, I.G., Drozda, M., Kim, B.Y., Ona, V., Li, M., Sarang, S., Friedlander, R.M., Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice (2002) Nature, 417, pp. 74-78; Zingarelli, B., Szabo, C., Salzman, A.L., Reduced oxidative and nitrosative damage in murine experimental colitis in the absence of inducible nitric oxide synthase (1999) Gut, 45, pp. 199-209

PY - 2009

Y1 - 2009

N2 - In addition to its antimicrobial activity, minocycline exerts anti-inflammatory effects in several disease models. However, whether minocycline affects the pathogenesis of inflammatory bowel disease has not been determined. We investigated the effects of minocycline on experimental colitis and its underlying mechanisms. Acute and chronic colitis were induced in mice by treatment with dextran sulfate sodium (DSS) or trinitrobenzene sulfonic acid (TNBS), and the effect of minocycline on colonic injury was assessed clinically and histologically. Prophylactic and therapeutic treatment of mice with minocycline significantly diminished mortality rate and attenuated the severity of DSS-induced acute colitis. Mechanistically, minocycline administration suppressed inducible nitric oxide synthase (iNOS) expression and nitrotyrosine production, inhibited proinflammatory cytokine expression, repressed the elevated mRNA expression of matrix metalloproteinases (MMPs) 2, 3, 9, and 13, diminished the apoptotic index in colonic tissues, and inhibited nitric oxide production in the serum of mice with DSS-induced acute colitis. In DSS-induced chronic colitis, minocycline treatment also reduced body weight loss, improved colonic histology, and blocked expression of iNOS, proinflammatory cytokines, and MMPs from colonic tissues. Similarly, minocycline could ameliorate the severity of TNBS-induced acute colitis in mice by decreasing mortality rate and inhibiting proinflammatory cytokine expression in colonic tissues. These results demonstrate that minocycline protects mice against DSS- and TNBS-induced colitis, probably via inhibition of iNOS and MMP expression in intestinal tissues. Therefore, minocycline is a potential remedy for human inflammatory bowel diseases. © 2009 Elsevier Inc. All rights reserved.

AB - In addition to its antimicrobial activity, minocycline exerts anti-inflammatory effects in several disease models. However, whether minocycline affects the pathogenesis of inflammatory bowel disease has not been determined. We investigated the effects of minocycline on experimental colitis and its underlying mechanisms. Acute and chronic colitis were induced in mice by treatment with dextran sulfate sodium (DSS) or trinitrobenzene sulfonic acid (TNBS), and the effect of minocycline on colonic injury was assessed clinically and histologically. Prophylactic and therapeutic treatment of mice with minocycline significantly diminished mortality rate and attenuated the severity of DSS-induced acute colitis. Mechanistically, minocycline administration suppressed inducible nitric oxide synthase (iNOS) expression and nitrotyrosine production, inhibited proinflammatory cytokine expression, repressed the elevated mRNA expression of matrix metalloproteinases (MMPs) 2, 3, 9, and 13, diminished the apoptotic index in colonic tissues, and inhibited nitric oxide production in the serum of mice with DSS-induced acute colitis. In DSS-induced chronic colitis, minocycline treatment also reduced body weight loss, improved colonic histology, and blocked expression of iNOS, proinflammatory cytokines, and MMPs from colonic tissues. Similarly, minocycline could ameliorate the severity of TNBS-induced acute colitis in mice by decreasing mortality rate and inhibiting proinflammatory cytokine expression in colonic tissues. These results demonstrate that minocycline protects mice against DSS- and TNBS-induced colitis, probably via inhibition of iNOS and MMP expression in intestinal tissues. Therefore, minocycline is a potential remedy for human inflammatory bowel diseases. © 2009 Elsevier Inc. All rights reserved.

KW - Colitis

KW - Dextran sulfate sodium

KW - Inducible nitric oxide synthase

KW - Inflammatory bowel diseases

KW - Matrix metalloproteinases

KW - Minocycline

KW - Trinitrobenzene sulfonic acid

KW - antibiotic agent

KW - collagenase 3

KW - dextran sulfate

KW - gelatinase A

KW - gelatinase B

KW - inducible nitric oxide synthase

KW - matrix metalloproteinase

KW - messenger RNA

KW - minocycline

KW - nitric oxide

KW - stromelysin

KW - trinitrobenzenesulfonic acid

KW - acute disease

KW - animal experiment

KW - animal model

KW - antiinflammatory activity

KW - article

KW - chronic disease

KW - colitis

KW - controlled study

KW - disease severity

KW - drug dose comparison

KW - drug dose increase

KW - enteritis

KW - experimental model

KW - immune response

KW - immunohistochemistry

KW - intestine cell

KW - male

KW - mortality

KW - mouse

KW - nonhuman

KW - real time polymerase chain reaction

KW - reverse transcription polymerase chain reaction

KW - Animals

KW - Anti-Bacterial Agents

KW - Anti-Inflammatory Agents

KW - Cytokines

KW - Dextran Sulfate

KW - Disease Models, Animal

KW - Enzyme Inhibitors

KW - Inflammation

KW - Male

KW - Matrix Metalloproteinases

KW - Metronidazole

KW - Mice

KW - Mice, Inbred BALB C

KW - Mice, Inbred C57BL

KW - Nitric Oxide Synthase Type II

KW - RNA, Messenger

KW - Species Specificity

KW - Survival Analysis

KW - Trinitrobenzenesulfonic Acid

KW - Mus

U2 - 10.1016/j.taap.2009.02.026

DO - 10.1016/j.taap.2009.02.026

M3 - Article

SN - 0041-008X

VL - 237

SP - 69

EP - 82

JO - Toxicology and Applied Pharmacology

JF - Toxicology and Applied Pharmacology

IS - 1

ER -

Minocycline attenuates experimental colitis in mice by blocking expression of inducible nitric oxide synthase and matrix metalloproteinases

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this